Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Apr 15, 2026; 18(4): 116365
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.116365
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.116365
Table 1 Key laboratory values before and at presentation
| Parameter | May 2024 (baseline) | September 2024 to October 2024 (acute presentation) |
| Hemoglobin (g/dL) | 13.0 | 5.2 |
| MCV (fL) | 86 | 68.7 (microcytic) |
| Ferritin (ng/mL) | 137 | 26.4 (low-normal) |
| Reticulocytes (%) | - | 1.2 |
| White blood count (× 109/L) | 14.9 | - (not significantly changed) |
| BCR-ABL1 (%) | 0.0061 | < 0.0030 (stable MR4.5) |
| Bilirubin (total/direct; mg/dL) | - | 0.24/0.11 |
| Haptoglobin (mg/dL) | - | 365 (high) |
| Lactate dehydrogenase (U/L) | - | 168 |
| FIT | - | Negative |
| Vitamin B12/folate | Normal | Normal |
- Citation: Najdi T, Seif S, Khoury D, Kahwagi A, Wehbe P, Karam R, El Halabi L, Slim R, Chakhtoura G, Trak V, Eid R. Occult intestinal angiosarcoma presenting as refractory anemia during tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A case report. World J Gastrointest Oncol 2026; 18(4): 116365
- URL: https://www.wjgnet.com/1948-5204/full/v18/i4/116365.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i4.116365